Identification of the molecular function of tripartite motif containing 58 in human lung cancer

Shi,Yuan-Xiang

doi:10.3892/ol.2021.12946

Identification of the molecular function of tripartite motif containing 58 in human lung cancer

Authors:
- Yuan-Xiang Shi
View Affiliations

Affiliations: Institute of Clinical Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China
Published online on: July 28, 2021 https://doi.org/10.3892/ol.2021.12946
Article Number: 685
Copyright : © Shi . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a major public health problem worldwide, with a high associated incidence and mortality. In the present study, novel epigenetic signatures were identified through genome‑wide DNA methylation microarrays. The results revealed that tripartite motif containing 58 (TRIM58), a potential tumor suppressor gene exhibited high methylation and low expression in lung cancer tissue samples compared with normal tissues. Receiver operating characteristic curve analysis demonstrated that TRIM58 may be a promising early diagnostic indicator of lung cancer. In addition, the present study analyzed the role of TRIM58 in tumorigenesis and development in lung cancer A549 cells. Wound healing assay and transwell migration assay were used to investigate cell migration, and flow cytometry analysis was used to detect apoptosis. Silencing TRIM58 accelerated the proliferation and migration of lung cancer cells. In contrast, the overexpression of TRIM58 significantly inhibited the proliferation and migration of lung cancer cells and promoted apoptosis. Gene set enrichment analysis revealed that TRIM58 expression was negatively correlated with MYC targets, G2M checkpoints and the mTORC1 signaling pathway. These results of the present study suggested that TRIM58, a potential tumor suppressor gene may serve as a novel diagnostic biomarker and therapeutic target in human lung cancer.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
3	McIntyre A and Ganti AK: Lung cancer-A global perspective. J Surg Oncol. 115:550–554. 2017. View Article : Google Scholar : PubMed/NCBI
4	Liloglou T, Bediaga NG, Brown BR, Field JK and Davies MP: Epigenetic biomarkers in lung cancer. Cancer Lett. 342:200–212. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wood SL, Pernemalm M, Crosbie PA and Whetton AD: The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar : PubMed/NCBI
6	Visconti R, Morra F, Guggino G and Celetti A: The between now and then of lung cancer chemotherapy and immunotherapy. Int J Mol Sci. 18:E13742017. View Article : Google Scholar
7	Shi YX, Yin JY, Shen Y, Zhang W, Zhou HH and Liu ZQ: Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Sci Rep. 7:80722017. View Article : Google Scholar : PubMed/NCBI
8	Michalak EM, Burr ML, Bannister AJ and Dawson MA: The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 20:573–589. 2019. View Article : Google Scholar : PubMed/NCBI
9	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002. View Article : Google Scholar : PubMed/NCBI
10	Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
11	Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, et al: Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 14:343–357. 2019. View Article : Google Scholar : PubMed/NCBI
12	Choo KB: Epigenetics in disease and cancer. Malays J Pathol. 33:61–70. 2011.PubMed/NCBI
13	Schübeler D: Function and information content of DNA methylation. Nature. 517:321–326. 2015. View Article : Google Scholar : PubMed/NCBI
14	Shinjo K and Kondo Y: Targeting cancer epigenetics: Linking basic biology to clinical medicine. Adv Drug Deliv Rev. 95:56–64. 2015. View Article : Google Scholar : PubMed/NCBI
15	Jones PA, Issa JPJ and Baylin S: Targeting the cancer epigenome for therapy. Nat Rev Genet. 17:630–641. 2016. View Article : Google Scholar : PubMed/NCBI
16	Schiffmann I, Greve G, Jung M and Lübbert M: Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics. 11:858–870. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hatakeyama S: TRIM family proteins: Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
19	Napolitano LM and Meroni G: TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wang S, Zhang Y, Huang J, Wong CC, Zhai J, Li C, Wei G, Zhao L, Wang G, Wei H, et al: TRIM67 activates p53 to suppress colorectal cancer initiation and progression. Cancer Res. 79:4086–4098. 2019.PubMed/NCBI
21	Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer. Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
22	Meroni G and Diez-Roux G: TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases. BioEssays. 27:1147–1157. 2005. View Article : Google Scholar : PubMed/NCBI
23	Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al: The tripartite motif family identifies cell compartments. EMBO J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
24	Short KM and Cox TC: Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem. 281:8970–8980. 2006. View Article : Google Scholar : PubMed/NCBI
25	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
26	Shi YX, Wang Y, Li X, Zhang W, Zhou HH, Yin JY and Liu ZQ: Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer. BMC Genomics. 18:9012017. View Article : Google Scholar : PubMed/NCBI
27	Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, et al: An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol. 10:1037–1048. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mansfield AS, Wang L, Cunningham JM, Jen J, Kolbert CP, Sun Z and Yang P: DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. Cancer Genet. 208:253–260. 2015. View Article : Google Scholar : PubMed/NCBI
29	Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al: Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22:1197–1211. 2012. View Article : Google Scholar : PubMed/NCBI
30	Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al: Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5:R802004. View Article : Google Scholar : PubMed/NCBI
31	Smyth GK: limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. pp. 397–420. Springer; New York, NY: 2005, View Article : Google Scholar
32	Ghosh D: Incorporating the empirical null hypothesis into the Benjamini-Hochberg procedure. Stat Appl Genet Mol Biol. 11:/j/sagmb.2012.11.issue-4/1544-6115.1735/1544-6115.1735.xml2012.doi: 10.1515/1544-6115.1735. View Article : Google Scholar : PubMed/NCBI
33	Goldman M, Craft B, Swatloski T, Cline M, Morozova O, Diekhans M, Haussler D and Zhu J: The UCSC Cancer Genomics Browser: Update 2015. Nucleic Acids Res. 43:D812–D817. 2015. View Article : Google Scholar : PubMed/NCBI
34	Huang WY, Hsu SD, Huang HY, Sun YM, Chou CH, Weng SL and Huang HD: MethHC: A database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 43:D856–D861. 2015. View Article : Google Scholar : PubMed/NCBI
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
36	Watanabe M and Hatakeyama S: TRIM proteins and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
37	Zhan W and Zhang S: TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets. Life Sci. 268:1189852021. View Article : Google Scholar : PubMed/NCBI
38	Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, Some M, Yanagisawa K, Takahashi T, Osada H, et al: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 23:5360–5370. 2004. View Article : Google Scholar : PubMed/NCBI
39	Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
40	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
41	Mari-Alexandre J, Diaz-Lagares A, Villalba M, Juan O, Crujeiras AB, Calvo A and Sandoval J: Translating cancer epigenomics into the clinic: Focus on lung cancer. Transl Res. 189:76–92. 2017. View Article : Google Scholar : PubMed/NCBI
42	Clark SJ and Melki J: DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene. 21:5380–5387. 2002. View Article : Google Scholar : PubMed/NCBI
43	You JS and Jones PA: Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell. 22:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
44	Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J, et al: A novel epigenetic signature for early diagnosis in lung cancer. Clin Cancer Res. 22:3361–3371. 2016. View Article : Google Scholar : PubMed/NCBI
45	Liu TY, Chen J, Shang CL, Shen HW, Huang JM, Liang YC, Wang W, Zhao YH, Liu D, Shu M, et al: Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer. J Exp Clin Cancer Res. 35:1702016. View Article : Google Scholar : PubMed/NCBI
46	Chen N, Balasenthil S, Reuther J and Killary AM: DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res. 74:5683–5689. 2014. View Article : Google Scholar : PubMed/NCBI
47	Tamaddoni A, Mohammadi E, Sedaghat F, Qujeq D and As'Habi A: The anticancer effects of curcumin via targeting the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Pharmacol Res. 156:1047982020. View Article : Google Scholar : PubMed/NCBI
48	Lane HA and Breuleux M: Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol. 21:219–229. 2009. View Article : Google Scholar : PubMed/NCBI
49	Tansey WP: Mammalian MYC proteins and cancer. New J Sci. 2014.1–27. 2014.https://doi.org/10.1155/2014/757534 View Article : Google Scholar